Valinor Drug Patent Portfolio
Valinor owns 1 orange book drug protected by 6 US patents Given below is the list of Valinor's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9012469 | Crystalline naloxol-peg conjugate | 02 Apr, 2032 | Active |
| US7786133 | Chemically modified small molecules | 16 Sep, 2028 | Active |
| US8067431 | Chemically modified small molecules | 16 Dec, 2024 | Active |
| US7056500 | Polymer conjugates of opioid antagonists | 29 Jun, 2024 | Expired |
| US7662365 | Polymer conjugates of opioid antagonists | 18 Oct, 2022 | Expired |
| US8617530 | Polymer conjugates of opioid antagonists | 18 Oct, 2022 | Expired |
Latest Legal Activities on Valinor's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Valinor.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Sep, 2022 | US9012469 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Jan, 2022 | US7786133 |
|
Patent Term Extension Certificate
Critical
| 06 Dec, 2021 | US7786133 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 Jul, 2021 | US7662365 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 May, 2021 | US8617530 |
| Mail Certificate of Correction Memo | 06 May, 2021 | US9012469 |
| Certificate of Correction Memo | 05 May, 2021 | US9012469 |
| Post Issue Communication - Certificate of Correction | 05 May, 2021 | US9012469 |
| Notice of Final Determination -Election Required | 16 Feb, 2021 | US7786133 |
| Notice of Final Determination -Election Required | 16 Feb, 2021 | US7662365 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 08 Jul, 2020 | US9012469 |
|
Correspondence Address Change
Critical
| 07 Jul, 2020 | US9012469 |
|
FDA Final Eligibility Letter
Critical
| 07 Mar, 2019 | US7786133 |
|
FDA Final Eligibility Letter
Critical
| 07 Mar, 2019 | US7662365 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Sep, 2018 | US9012469 |
Valinor's Drug Patent Litigations
Valinor's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 15, 2015, against patent number US7786133. The petitioner Neptune Generics, LLC, challenged the validity of this patent, with NEKTAR THERAPEUTICS as the respondent. Click below to track the latest information on how companies are challenging Valinor's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7786133 | October, 2015 |
Terminated-Denied
(27 Apr, 2016)
| NEKTAR THERAPEUTICS | Neptune Generics, LLC |
Valinor Drug Patents' Oppositions Filed in EPO
Valinor drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 22, 2014, by Generics (Uk) Ltd (Trading As Mylan). This opposition was filed on patent number EP04814802A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP11829686A | Sep, 2016 | ABG Patentes, S.L. | Patent maintained as amended |
| EP11829686A | Sep, 2016 | Stada-Arzneimittel Aktiengesellschaft | Patent maintained as amended |
| EP11829686A | Sep, 2016 | Generics [UK] Limited | Patent maintained as amended |
| EP04814802A | Oct, 2014 | Generics (UK) Ltd (trading as Mylan) | Opposition rejected |
Valinor's Family Patents
Valinor Drug List
Given below is the complete list of Valinor's drugs and the patents protecting them.
1. Movantik
Movantik is protected by 6 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9012469 | Crystalline naloxol-peg conjugate |
02 Apr, 2032
(7 years from now)
| Active |
| US7786133 | Chemically modified small molecules |
16 Sep, 2028
(3 years from now)
| Active |
| US8067431 | Chemically modified small molecules |
16 Dec, 2024
(30 days from now)
| Active |
| US7056500 | Polymer conjugates of opioid antagonists |
29 Jun, 2024
(4 months ago)
| Expired |
| US7662365 | Polymer conjugates of opioid antagonists |
18 Oct, 2022
(2 years ago)
| Expired |
| US8617530 | Polymer conjugates of opioid antagonists |
18 Oct, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Movantik's drug page